Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PMV Pharmaceuticals

Explore full profile

A Doylestown, Penn-based developer of p53-targeted small molecule drugs for the treatment of cancer

Cranbury Township, United StatesFounded 2013Biotech & Life Sciences
Total funding $100–500M Disclosed equity funding

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a pioneering biotechnology company focused on developing innovative treatments for cancer. The company specializes in creating first-in-class p53 regulators, targeting the most commonly mutated protein in human cancers. By harnessing over three decades of p53 biology, PMV Pharma combines a unique biological understanding with a strong focus on pharmaceutical development.

Read full description

PMV Pharma operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from various forms of cancer. The company's business model revolves around the research, development, and commercialization of novel cancer therapies. Revenue is generated through the successful development and eventual sale or licensing of their proprietary treatments.

The company is led by a team of industry and academic thought leaders who are dedicated to discovering new treatments for human diseases. This leadership team brings together extensive experience in both scientific research and pharmaceutical development, ensuring a robust approach to tackling cancer.

PMV Pharma's core mission is to harness the power of p53 to treat cancer, offering hope and potential cures to millions of patients worldwide. The company is headquartered in Cranbury, NJ, and continues to make significant strides in the field of oncology.

Source: Dealroom company data

At a glance

Founded
2013
Headquarters
Cranbury Township, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Latest news

Press, funding announcements and product moves mentioning PMV Pharmaceuticals.

See all news

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later8 investors entered at this stage

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States95.7%
🇦🇺 Australia2.1%
🇨🇭 Switzerland2.1%
3 countries shown
Web traffic by country
6.6K monthly visits
across markets
🇺🇸 United States68.2%
🇯🇵 Japan25.8%
🇨🇦 Canada3%
🇮🇳 India3%
Top 4 markets shown

Patents

Estimated portfolio value
$22M

20 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PMV Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PMV Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.